Events - Pharvaris N.V.

Upcoming Events

Sep 15, 2026 7:45 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Sep 16, 2026 8:00 AM EDT

H.C. Wainwright 28th Annual Global Investment Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Past Events

Oct 2 - Oct 5, 2024

British Society Allergy and Clinical Immunology Conference (BSCAI 2024)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial (Oral) 2.7 MB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 234.4 KB

Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life in Patients With Hereditary Angioedema 717 KB

Relief and Resolution of Hereditary Angioedema Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release 626.4 KB

Sep 27 - Sep 29, 2024

World Allergy Congress 2024

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 879.5 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 735.2 KB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 469.2 KB

Sep 26 - Sep 28, 2024

Deutscher Allergiekongress

Supporting Materials

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.6 MB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.2 MB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 1.2 MB

Characterizing Use of On-Demand Treatment Among People Living With Hereditary Angioedema in Germany 469.2 KB

Sep 13 - Sep 14, 2024

CIIC Fall 2024 Conference

Supporting Materials

Long-Term Safety and Efficacy of Prophylactic Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Hereditary Angioedema: Results of the CHAPTER-1 Open Label Extension Study 517.4 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 734.1 KB

Sep 5 - Sep 6, 2024

Bradykinin Symposium 2024

Supporting Materials

Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat 429 KB

Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL 337.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis 183.8 KB

Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results 622 KB

Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results 239.2 KB

Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis 186.3 KB

Clinical Trials Conformity with AURORA COS: a systematic literature review 156 KB

Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant 765.8 KB

The bradykinin challenge model translates across rat, monkey and human 1.5 MB

Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat 752.5 KB

A novel kinin biomarker assay for characterization of bradykinin-mediated disorders 905 KB

A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders 865.2 KB

Sep 5, 2024 8:00 AM EDT

Pharvaris Corporate Update

Click for Webcast

Supporting Materials

Pharvaris Corporate Update Presentation 2 MB

Jun 28, 2024 9:00 AM EDT

2024 Annual General Meeting of Shareholders

Supporting Materials

Annual Report 2023 2.8 MB

Convening Notice and Agenda 58.2 KB

Voting Proxy 44.6 KB

Executed Minutes 474.2 KB

May 31 - Jun 3, 2024

European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.5 MB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 1.5 MB

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design 210.8 KB

Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks 134.6 KB

Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat 170.9 KB

Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases 358.6 KB

May 30 - Jun 2, 2024

2024 Eastern Allergy Conference (EAC)

Supporting Materials

Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema 212.3 KB

May 22 - May 24, 2024

20th Annual Congress of International Drug Discovery Science and Technology (IDDST)

Supporting Materials

Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema 1.3 MB

Pagination

First page
Previous page
…
Page 5
Page 6
Current page 7
Page 8
Page 9
…
Next page
Last page